Wilson Sonsini Goodrich & Rosati advised NEA and Abingworth on the transaction. Escient Pharmaceuticals announced that it had raised $120 million through a Series C Financing...
Escient Pharmaceuticals’ $120 Million Series C Financing
Rezo Therapeutics’ $78 Million Series A Financing
Wilson Sonsini represented lead investors SR One and Norwest in the transaction. Rezo Therapeutics, a biotechnology company pioneering the integrated mapping of disease networks for precision...
Inversago Pharma’s $70 Million Series C Financing
White & Case and Osler, Hoskin & Harcourt LLP advised Inversago Pharma Inc. on the deal, while Wilson Sonsini advised NEA. Inversago Pharma Inc., a clinical-stage...
Harmonic Discovery’s $8 Million Seed Funding
Wilson Sonsini Goodrich & Rosati advised Harmonic Discovery on the deal. Harmonic Discovery, a therapeutics company building an integrated computational and experimental platform for kinase drug...
1859’s $40 Million Series A Funding Round
Wilson Sonsini Goodrich & Rosati advised 1859, Inc. on the deal. 1859, Inc., a platform company combining artificial intelligence and empirical pico-scale screening data at scale...
Simcha Therapeutics’ $40 Million Series B Financing
Wilson Sonsini Goodrich & Rosati advised SR One on the deal. Simcha Therapeutics, a biotechnology company developing cytokine-based cancer immunotherapies, announced the closing of a $40...
858 Therapeutics’ $60 Million Series A Financing
Wilson Sonsini Goodrich & Rosati advised New Enterprise Associates (NEA) and Versant Ventures on the deal. 858 Therapeutics announced the completion of a $60 million Series...
ADARx’s $75 Million Series B Financing
Wilson Sonsini Goodrich & Rosati advised SR One Capital Management on the deal. ADARx Pharmaceuticals, Inc., a biotechnology company developing RNA targeting therapeutics, announced the completion...
Attralus’ $116 Million Series B Financing
Wilson Sonsini Goodrich & Rosati advised Logos Capital on the deal while Sidley represented Attralus, Inc. Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines...
ARS Pharmaceuticals’ $55 Million Series D Financing
Wilson Sonsini Goodrich & Rosati advised SR One on the deal. ARS Pharmaceuticals, Inc., a pharmaceutical company dedicated to empowering at-risk patients and caregivers to better...
Zentera Therapeutics’ $75 Million Series B Financing
Wilson Sonsini Goodrich & Rosati advised Tybourne Capital Management on the deal. Zentera Therapeutics, a clinical-stage biopharmaceutical company, completed a $75 million Series B financing. Founding investors...
Arena Pharmaceuticals’ Strategic Collaboration with Aristea Therapeutics
Wilson Sonsini Goodrich & Rosati advised Aristea Therapeutics on the deal. Arena Pharmaceuticals, Inc. and Aristea Therapeutics, Inc. announced a strategic collaboration to advance the clinical...